We have developed a way using 3 transcription proteins, our ELP construct and the cancer biomarker MR-1 to reprogram cancer cells into T-cells that present the antigen for the cancer and will continue to attack that tumor as well as circulate to find metastasis of similar tumors. Off target effects will produce naïve T-cells that we can educate with our topical technology. We transfect S. Epidermidis with MR-1 and make into a probiotic face cream. Colonies of naïve T-cells aggregate under these colonies of staph epidermidis (the most ubiquitous bacteria in your skin biome) and our topical educates these T-cells. This gives you a T-cell therapy against 85% of cancers.

This novel technology gives you the ability to reprogram cells back to their pluripotent state without the use of viral vectors. This is highly sought after because it gives you the ability to use stem therapies in clinical trials without viral vectors being involved. We are also using this technology ourselves both in our direct-to-consumer products and to make off the shelf HILO cells for islet cell transplants for Type 1 Diabetes.

We have two therapeutics that reverse periodontal disease. The first is our exosome technology which are IL-10 exosomes in a thermally responsive biomaterial. The second one is an ELP IL-10 construct in the same hydrogel that should provide the same results at a significantly reduced cost. We know this works because we have 20 years of regenerative periodontal therapies experience.

We have developed a slight variation on our ELP construct which allows us to get silk proteins that self-assemble into nano particles at body temperature that then form into sheets covering the wound, to this we attach four proteins that are necessary for wound healing. These self-assemble into an extracellular matrix sheet that contains all the proteins necessary for wounds to heal even in the absence of good nerve and blood supply.

We have developed three therapeutics for this orphan disease based on an interest by the EB Research Foundation. The first one involves a topical gene therapy which replaces the defective genes (ELP – COL7A1 construct). The second is a topical wound care spray that contains TIMP-1 and reduces the time of wound healing by half. The third one corrects the autoimmune imbalance set up by the collagen fragments (this is an MMP-TIMP imbalance that causes the collagen to break down faster than it is produced. This is the main cause of the symptoms that nobody is looking at.

We have two therapies which have been shown to reverse MS. One is a treatment, and one reverses the disease. The first one is an IL-10 exosome in an inhalable delivery vehicle. We have a peer reviewed paper in ACS Nano Biotechnology showing that this systematically regenerates the myelin sheath of the spinal cord and restores mobility. This doesn’t however address the autoimmune component of the disease. Our second therapeutic utilizes our autoimmune platform which attaches MOG protein to our ELP construct. We attach PGAL to the other end. This forms a nano particle at body temperature with the MOG protein at the center and PGAL on the outside. The PGAL shuttles the construct to the liver where it is broken down recognized as self and the autoimmune response is trained out of the patient by selectively removing the memory of the T-cells. This approach works for any autoimmune disease as long as you know the offending protein.

Our world-renowned scientists have been working in T1D for the last 30 years. Jonathan Lakey, PhD, was instrumental in the very first islet cell transplant in the year 2000 and was published in The New England Journal of Medicine. Twenty-five years later we now have a way to train the autoimmune disease out of the patient and restore them to a normal insulin response. This therapy utilizes our autoimmune platform by attaching the four autoantibodies to the ELP and to PGAL which shuttles the construct to the liver and trains the autoimmune response out of the patient by removing the memory of the T-cells. We think this will take 4-6 months of treatment which gives time to take a skin biopsy from the patient and convert those into patient specific HILO cells for an islet cell transplant once the autoimmune part of the disease is addressed. We can make these HILO cells using our ELP-OSK construct which completely avoids viral vectors.